{"id":"W2105562405","doi":"10.1186/2051-1426-2-2","title":"Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study","year":2014,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Pfizer; Bristol-Myers Squibb; Genentech; Amgen","keywords":"Sorafenib; Medicine; Renal cell carcinoma; Pharmacokinetics; Pharmacodynamics; Pharmacology; Internal medicine; Rash; Oncology; Immunotherapy; Toxicity; Gastroenterology; Hepatocellular carcinoma; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002355308,0.001961988,0.00252652,0.0005291364,0.00041208,0.001047282,0.001139674,0.001300033,0.00247804],"category_scores_gemma":[0.001084296,0.0007354579,0.001444587,0.0004630377,0.001073133,0.0008862831,0.0003268771,0.002630227,0.0006609506],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009907708,"about_ca_system_score_gemma":0.002240615,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000930966,"about_ca_topic_score_gemma":0.002136972,"domain_scores_codex":[0.9993593,0.0003160773,0.00003014175,0.0001030119,0.00008822948,0.0001031611],"domain_scores_gemma":[0.9991648,0.0001443872,0.0001782998,0.000071995,0.00006766097,0.0003729113],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5052513,0.2343794,0.00695204,0.003033332,0.003102384,0.001138504,0.0006054213,0.00457584,0.1144553,0.0003019386,0.00549049,0.1207141],"study_design_scores_gemma":[0.4367766,0.5482996,0.006032283,0.00003828017,0.0004982138,0.0005762631,0.00004543573,0.001128194,0.004675062,0.00008292167,0.001815666,0.00003141031],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9922373,0.003419304,0.0005398155,0.0004466926,0.0001359729,0.001987613,0.0004751571,0.00008509633,0.0006730079],"genre_scores_gemma":[0.988009,0.003793624,0.002081615,0.0007526836,0.0003503607,0.002111181,0.001412744,0.00003972101,0.001449042],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00252652,"threshold_uncertainty_score":0.01245618,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04145423578145745,"score_gpt":0.3631940069784667,"score_spread":0.3217397711970092,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}